Why health officials aren't afraid of bird flu

Published Date: 02 Mar 2023

A new strain of flu, easily spread among wild birds, is spreading to new parts of the world, infecting and killing many species, raising fears of a new pandemic like COVID-19.

Read Full News

Todays Updates


This Week on NeurologyLive® — November 16, 2026 Isabella Ciccone, MPH


Here's some of what is coming soon to NeurologyLive® this week.

Recognizing Early-Onset Alzheimer Disease and the Role of Blood Biomarkers Allison B. Reiss, MD, Isabella Ciccone, MPH


Allison B. Reiss, MD, associate professor of medicine at NYU Grossman Long Island School of Medicine discussed the often-overlooked early signs of early-onset Alzheimer disease.

FDA Approves Gefurulimab for Generalized Myasthenia Gravis Marco Meglio


Gefurulimab (Klygefa), a once-weekly, self-administered complement C5 inhibitor from Alexion and AstraZeneca, is now approved in the US for adults with AChR-antibody-positive generalized myasthenia gravis.

Cenobamate sNDA Seeks FDA Approval for Generalized Seizures Marco Meglio


A new FDA filing seeks to expand cenobamate's epilepsy indication to primary generalized tonic-clonic seizures, based on positive phase 3 trial data.

Benjamin Greenberg, MD, MHS, on Highlights From the 2026 Rare Neuroimmune Disorders Symposium Benjamin Greenberg, MD, Isabella Ciccone, MPH


The professor of neurology at UT Southwestern Medical Center discussed emerging trials, proposed changes to myelitis diagnostic criteria and nomenclature, and the unmet needs raised by patients at this year’s symposium.

Roche Launches Phase 2 TARBELA-AD Trial of NLRP3 Inhibitor in Alzheimer Disease Marco Meglio


A new global phase 2 trial, TARBELA-AD, will test RG6434, Roche's investigational oral NLRP3 inflammasome inhibitor, in adults with early symptomatic Alzheimer disease.

Trial Enrollment Complete for Pivotal Phase 2/3 Study of CB03-154 in ALS Marco Meglio


A pivotal phase 2/3 trial of Zhimeng Biopharma's CB03-154, an oral KCNQ2/3 potassium channel opener, has completed enrollment in amyotrophic lateral sclerosis.

Todays Updates


This Week on NeurologyLive® — November 16, 2026 Isabella Ciccone, MPH


Here's some of what is coming soon to NeurologyLive® this week.

Recognizing Early-Onset Alzheimer Disease and the Role of Blood Biomarkers Allison B. Reiss, MD, Isabella Ciccone, MPH


Allison B. Reiss, MD, associate professor of medicine at NYU Grossman Long Island School of Medicine discussed the often-overlooked early signs of early-onset Alzheimer disease.

FDA Approves Gefurulimab for Generalized Myasthenia Gravis Marco Meglio


Gefurulimab (Klygefa), a once-weekly, self-administered complement C5 inhibitor from Alexion and AstraZeneca, is now approved in the US for adults with AChR-antibody-positive generalized myasthenia gravis.

Cenobamate sNDA Seeks FDA Approval for Generalized Seizures Marco Meglio


A new FDA filing seeks to expand cenobamate's epilepsy indication to primary generalized tonic-clonic seizures, based on positive phase 3 trial data.

Benjamin Greenberg, MD, MHS, on Highlights From the 2026 Rare Neuroimmune Disorders Symposium Benjamin Greenberg, MD, Isabella Ciccone, MPH


The professor of neurology at UT Southwestern Medical Center discussed emerging trials, proposed changes to myelitis diagnostic criteria and nomenclature, and the unmet needs raised by patients at this year’s symposium.

Roche Launches Phase 2 TARBELA-AD Trial of NLRP3 Inhibitor in Alzheimer Disease Marco Meglio


A new global phase 2 trial, TARBELA-AD, will test RG6434, Roche's investigational oral NLRP3 inflammasome inhibitor, in adults with early symptomatic Alzheimer disease.

Trial Enrollment Complete for Pivotal Phase 2/3 Study of CB03-154 in ALS Marco Meglio


A pivotal phase 2/3 trial of Zhimeng Biopharma's CB03-154, an oral KCNQ2/3 potassium channel opener, has completed enrollment in amyotrophic lateral sclerosis.

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Kidney cancer: Understanding what a renal cell carcinoma diagnosis means

2.

Study opens up possibility of bespoke prostate cancer treatment

3.

Mosunetuzumab in Follicular Lymphoma: Durable Responses and Manageable Safety

4.

Imetelstat for MDS-relateret anemia er godkendt af Food and Drug Administrations panel.

5.

Lung Cancer Screening Rates in Eligible Adults Remain Low, Uneven


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot